VN December 2020
Vetnuus |Desember 2020 6 Leading Article The evolution of potent opioids in the field of wildlife immobilisation....<<< 05 The large injection volumes required also resulted in slow absorption and delayed onset of action, also making it unsuitable for use in antelope that tended to run after darting. Reckitt & Sons developed M99 and M183 in 1960 for research purposes. By 1963, Dr Harthoorn had started investigating the use of M99 and M183 in wildlife animals. M183 was essentially the acetylated form of M99 but its potency was significantly less than that of M99. M183 was useful in species where it was preferred that the animals remain on their feet e.g. giraffe, or when animals were in poor condition or debilitated and more sensitive to the side effects of M99. The use of M183 for research purposes was however, discontinued while research on the use of M99 (now etorphine) persisted. The main advantage of etorphine is that its potency and relative solubility in water allows for its use in small volumes. Originally, stable aqueous solutions containing 4-5 mg/ml of the powdered base were prepared and later, DMSO (dimethyl sulphoxide) was used to prepare solutions containing 10 mg/ml or more. DMSO is a solvent that penetrates intact skin and can carry opioids across the skin barrier, making these products dangerous to handle. Today, etorphine is available without the addition of DMSO in a concentration of 9.8 mg/ml (Captivon 98, Wildlife Pharmaceuticals (Pty) Ltd.). Dr Harthoorn and his team went on to investigate etorphine in combination with numerous tranquilisers and sedatives to counteract the initial excitement observed when etorphine was used as monotherapy. The addition of sedatives and/or tranquilisers also improved recoveries by providing a tranquilised plane into which the animal was raised when the etorphine was reversed. Despite a few disadvantages e.g. respiratory depression, severe hypertension in large species like rhino and elephant, a prolonged excitatory phase during induction, poor muscle relaxation in certain species and decreased rumen motility, etorphine soon became the immobilising agent of choice. During the time that etorphine was investigated in wildlife, Janssen Pharmaceutica developed and registered fentanyl for human use. In veterinary practice, this opioid was supplied as fentanyl citrate powder in 0,1 g and 1,0 g sachets and later, as a small animal formulation of droperidol-fentanyl that was marketed as InnovarVet®. Solutions of the powder could be prepared in concentrations of up to 30 mg/ml with higher concentrations of up to 50 mg/ml prepared with DMSO. The advantage that fentanyl has over etorphine is its rapid onset of action (3-5 minutes), lower incidence of respiratory depression and lower doses of antagonist required for reversal. The significantly lower potency of fentanyl in comparison to etorphine (15 mg fentanyl = 1 mg etorphine) however, means that it has a lower knock-down effect and needs to be used in combinations in order to achieve complete recumbency. Fentanyl also has a very short duration of action (< 30 minutes) and is not effective in equids. Soon after its synthesis in 1972 by Janssen Pharmaceutica, carfentanil was used for the immobilisation of wildlife. Carfentanil is the most potent opioid known (100x more potent than fentanyl). Its potency allows for very quick inductions and a long duration of action. However, this long duration of action often results in renarcotization once the effect of the antagonist has worn off. A study in eland showed that the half-life of carfentanil is 7.7 hours in comparison to that of naltrexone where the half-life is 3.7 hours. In the early 1990s, the use of thiafentanil was investigated in the Kruger National Park by Dr Don Janssen from the San Diego Zoo Dr Joel Alves walking a rhino immobilised with etorphine and butorphanol Blesbok darted with etorphine
Made with FlippingBook
RkJQdWJsaXNoZXIy OTc5MDU=